Nothing is Impossible

We turn insoluble compounds into stable, water-compatible nanoparticles using our innovative FAST Technology—advancing health across pharma, nutra, and cosmetics.

0+
Formulations Developed
0+
Industries Served
0%
GRAS-Status Processing Materials
0nm
Typical Nanoparticle Size Range

About

FAST Technology

A clean, simple way to turn poorly soluble actives into uniform nanoparticles.

FAST (Facilitated Self-Assembling Technology) forms stable, self-assembled nanoparticles directly from hydrophobic bioactives—using only GRAS-status materials in processing and no polymer/lipid carriers, surfactants, metals, or stabilizers. No high-energy processing or specialized equipment.

Discover the science behind our innovation. Explore how FAST Nano Lab transforms research into real-world nanoparticle solutions.

What FAST Delivers

  • Uniform, water-compatible nanoparticles with tight size distribution and robust colloidal stability.

  • Typical development targets: Z-avg 50-300 nm (≤180 nm for carotenoids), ζ ≤ −30 mV (in water).

  • Single-active or hybrid (multi-active) nanoparticles for synergistic formulations.

Why It’s Different

Compared with emulsion/surfactant/lipid systems, FAST’s self-assembly simplifies labels and processing while maintaining stability and high active content.

GRAS Context Note

GRAS refers to the US Food and Drug Administration (FDA)’ definition of “Generally Considered as Safe”.

Solutions

From Concept to Scalable Nanoparticle Prototypes

FAST Nano Lab provides tailored solutions across pharmaceuticals, nutraceuticals, and cosmetics, turning insoluble actives into clean, stable, and scalable nanoparticle formulations—ready for real-world application.

Pharmaceuticals

Unlock challenging actives with carrier-free, self-assembling nanoparticles that enhance bioavailability and simplify formulation. Ideal for oral, topical, and oncology applications.

Nutraceuticals

Deliver clean-label, high-payload dispersions of lipophilic actives using only GRAS materials—perfect for shots, beverages, gummies, or capsules.

Cosmetics

Enhance skin penetration and product stability with uniform nanoparticles made without surfactants or stabilizers, keeping formulations elegant and label-friendly.

Transform Your Actives with FAST

Partner with Us to Redefine What’s Possible

Ready to convert your insoluble compounds into stable, high-performance nanoparticles? Connect with FAST Nano Lab today and discover a cleaner, smarter path from feasibility to formulation success.

Products & Services

Clean, Self-Assembled Nanoparticles

We offer ready-to-order nanoparticles, hybrid multi-active systems & custom formulation services—all processed using GRAS-status materials with no carriers, surfactants or stabilizers. From lab-scale testing to tailored conversions, our products are built for purity, precision & performance.

All samples we sell are for scientific research only.

Ready-to-Order Nanoparticles

Uniform, water-compatible nanoparticles of key hydrophobic actives for R&D and formulation trials.

Hybrid Nanoparticles

Multi-active blends co-assembled for synergistic performance across wellness and nutrition applications.

Custom Nanoparticle Service

Send your compound, and we’ll convert it into FAST nanoparticles—clean, stable, and ready to scale.

Quality & Documentation

Comprehensive COAs and test data for every batch to ensure reproducibility and regulatory readiness.

Ordering & Shipping

Secure, light-protected packaging with full documentation & handling guidelines.

Learn More

about our ready-made and custom nanoparticle solutions.

Meet Our Team

Leading Experts to Drive Forward a Growing Business

We have built a management and advisory team that comprises a strong blend of talent and experience in advanced technology, product development, clinical trials, federal funded research and development, and product commercialization.

Dr. Stephen Hsu, Ph.D.

(Founder, Chairman, and CEO)

World-renowned expert in green tea polyphenol research and inventor of patented green tea-derived products and medications that treat dry mouth, dandruff, hair loss, cold sores, and viral infections using natural ingredients. He has published over 100 peer-reviewed papers and books on green tea polyphenols and has developed and marketed more than 34 green tea-based products for oral health, skin care, sun protection, and nail health.

As founder of Camellix and its subsidiaries, Dr. Hsu has invented technologies and products for conditions like xerostomia and viral infections, supported by Phase II clinical trials. Highlights include the MighTeaFlow formula for dry mouth (2011 IADR/GSK Innovation in Oral Care Award), the AverTeaX formula for herpes labialis (post-Phase II trial), a 2014 TED speakership, and the 2015 Georgia Bio Innovation Award. His recent National Institutes of Health (NIH)-funded work on virucidal disinfectants yielded the first nontoxic surface spray against norovirus and coronavirus. In 2025, his team developed FAST (Facilitate Self-assembling Technology) nanotechnology, enabling the first all-GRAS (Generally Recognized as Safe) oral rinse and nasal mist products. Dr. Hsu leads research, development, and strategic growth for the company.

Dr. Jamie De Stefano, D.M.D., Ph.D.

(Founder and President)

Licensed periodontist, Chief Dental Officer, successful business owner, and investor. She drives business development, fundraising, and investment strategies. Her dental expertise was instrumental in developing dry mouth technologies, product pipelines, and patient-centered solutions. As a proven U.S. and international investor, she identifies partnerships and facilitates introductions to prospective investors. Dr. De Stefano has a track record of backing research projects that evolve into commercial successes.

Ms. Tracy Wang, B.S.

(Senior Vice President and CFO)

Accomplished business owner with expertise in management, marketing, human resources, and customer service. She has secured partnership deals with Cardinal Health to commercialize Camellix products and managed over $2 million in National Institutes of Health (NIH) research funding.

Dr. Douglas Dickinson, Ph.D.

(VP for Research and Director of Camellix Research Laboratory)

Dr. Dickinson, a long-term collaborator and co-investigator with Dr. Hsu, leads daily research and development at Camellix Research Laboratory. Their combined expertise has yielded unique green tea catechin-based products, including EC16 technology for virucidal and antiviral applications, and FAST nanotechnology. The team boasts a strong record of publications, grant funding, and partnerships with FDA-registered contract manufacturers.